1. ALLA AKTIER
  2. NYHETER
  3. VÄSTRA HAMNEN CORP. FINANCE

Västra Hamnen Corp. Finance

Nyheter Västra Hamnen Corp. Finance Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Gabather: Starting phase II clinical trial

  • Approval to initiate the financed TOTEMS study
  • Patient enrolment imminent

Gabather has announced the initiation of the TOTEMS study, a phase II clinical trial evaluating the drug candidate GT-002 in patients with schizophrenia spectrum disorders. The study is conducted at the Center for Neuropsychiatric Schizophrenia Research (CNSR) at the Copenhagen University Hospital. Positive preliminary results would be a great boon to the investment case, for now we wait patiently.

The full report is available here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://x.com/vhcorp_se)

Datum 2026-05-08, kl 08:00
Källa MFN